Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Sells 11,280 Shares of Company Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CAO Michael Megna sold 11,280 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $98.54, for a total value of $1,111,531.20. Following the transaction, the chief accounting officer directly owned 12,697 shares in the company, valued at approximately $1,251,162.38. The trade was a 47.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 0.5%

Kiniksa Pharmaceuticals International stock traded up $0.52 during midday trading on Thursday, hitting $96.28. The company’s stock had a trading volume of 368,716 shares, compared to its average volume of 705,367. The stock’s 50-day moving average price is $81.53 and its 200-day moving average price is $62.18. Kiniksa Pharmaceuticals International, plc has a 12 month low of $37.02 and a 12 month high of $99.31. The company has a market capitalization of $7.56 billion, a PE ratio of 74.06 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The company had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KNSA. First Trust Advisors LP grew its holdings in Kiniksa Pharmaceuticals International by 30.7% during the third quarter. First Trust Advisors LP now owns 13,455 shares of the company’s stock valued at $1,004,000 after purchasing an additional 3,164 shares during the last quarter. Resona Asset Management Co. Ltd. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the third quarter worth $449,000. Focus Advisor Solutions LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the third quarter worth $224,000. Voya Investment Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 5.5% during the 3rd quarter. Voya Investment Management LLC now owns 8,522 shares of the company’s stock worth $636,000 after buying an additional 445 shares during the period. Finally, Global Retirement Partners LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 315.5% during the 3rd quarter. Global Retirement Partners LLC now owns 428 shares of the company’s stock worth $32,000 after buying an additional 325 shares during the period. 53.95% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

KNSA has been the subject of several recent research reports. Citigroup increased their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. raised their price objective on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Wells Fargo & Company lifted their target price on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, October 28th. The Goldman Sachs Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Finally, Weiss Ratings lowered shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and an average price target of $100.57.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.